Taken together, these data demonstrate that cetuximab-arm of anti-EGFR/VEGFR2 BsAb function effectively by blocking EGFR-mediated signaling in cancer cells and ramucirumab-scFv segment of anti-EGFR/VEGFR2 BsAb can act convincingly by dysregulating VEGFR2-mediated activity in both MDA-MD-231 and HUVEC cells. This evidence concerns the gene EGFR and cancer.